Cargando…

P17-23. Enhanced expression of HIV antigens and improved antigen presentation after infection with replication competent attenuated vaccinia virus in vitro

Detalles Bibliográficos
Autores principales:	Quakkelaar, E, Redeker, A, Loof, N, Perdiguero, B, Heinen, P, Nieto, J, Esteban, M, Kibler, K, Jacobs, B, Pantaleo, G, Melief, C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767810/ http://dx.doi.org/10.1186/1742-4690-6-S3-P305

Ejemplares similares

Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors
por: Quakkelaar, Esther D., et al.
Publicado: (2011)

Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”
por: Kibler, Karen V., et al.
Publicado: (2019)

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
por: Jacobs, B, et al.
Publicado: (2009)

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles
por: Meador, Lydia R., et al.
Publicado: (2017)

INDUCTION OF SKIN RESISTANCE TO VACCINIA VIRUS IN RABBITS BY VACCINIA-SOLUBLE EARLY ANTIGENS
por: Ueda, Y., et al.
Publicado: (1973)

P17-05. Dealing with HIV-1 diversity
por: Rosario, M, et al.
Publicado: (2009)

STUDIES ON THE SOLUBLE PRECIPITABLE SUBSTANCES OF VACCINIA : III. THE PRECIPITIN RESPONSES OF RABBITS TO THE LS ANTIGEN OF VACCINIA
por: Wishart, F. O., et al.
Publicado: (1936)

THE LS-ANTIGEN OF VACCINIA : III. PHYSICAL-CHEMICAL PROPERTIES OF LS-ANTIGEN AND SOME OF ITS DEGRADATION PRODUCTS
por: Shedlovsky, Theodore, et al.
Publicado: (1943)

Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen
por: Knudsen, Maria L., et al.
Publicado: (2015)

P17-07. Insertion of a vaccinia virus host range (hr) gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens
por: Najera, JL, et al.
Publicado: (2009)

Involvement of the Cellular Phosphatase DUSP1 in Vaccinia Virus Infection
por: Cáceres, Ana, et al.
Publicado: (2013)

Development and Evaluation of Single Domain Antibodies for Vaccinia and the L1 Antigen
por: Walper, Scott A., et al.
Publicado: (2014)

T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells
por: Kedl, Ross M., et al.
Publicado: (2000)

Efficacy of the modified vaccinia Ankara virus vaccine and the replication-competent vaccine ACAM2000 in monkeypox prevention
por: Kandeel, Mahmoud, et al.
Publicado: (2023)

THE LS-ANTIGEN OF VACCINIA : IV. CHEMICAL ANALYSIS OF LS AND THE EFFECT OF CHYMOTRYPSIN ON LS
por: Smadel, Joseph E., et al.
Publicado: (1943)

Study of Vaccinia and Cowpox viruses' replication in Rac1-N17 dominant-negative cells
por: Salgado, Ana Paula Carneiro, et al.
Publicado: (2013)

Unpolarized Release of Vaccinia Virus and HIV Antigen by Colchicine Treatment Enhances Intranasal HIV Antigen Expression and Mucosal Humoral Responses
por: Zhang, Yan, et al.
Publicado: (2011)

Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C
por: Perdiguero, Beatriz, et al.
Publicado: (2013)

Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus
por: Arndt, William D., et al.
Publicado: (2016)

A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope()
por: Gordon, James, et al.
Publicado: (1991)

Cryo X-ray nano-tomography of vaccinia virus infected cells
por: Chichón, Francisco Javier, et al.
Publicado: (2012)

Small Hero with Great Powers: Vaccinia Virus E3 Protein and Evasion of the Type I IFN Response
por: Szczerba, Mateusz, et al.
Publicado: (2022)

Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses
por: Riederer, Stephanie, et al.
Publicado: (2021)

THE LS-ANTIGEN OF VACCINIA : I. INHIBITION OF L- AND S-ANTIBODIES BY SUBSTANCES IN TREATED VACCINE DERMAL FILTRATE
por: Smadel, Joseph E., et al.
Publicado: (1942)

THE LS-ANTIGEN OF VACCINIA : II. ISOLATION OF A SINGLE SUBSTANCE CONTAINING BOTH L- AND S-ACTIVITY
por: Shedlovsky, Theodore, et al.
Publicado: (1942)

Defining antigen targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans
por: Grifoni, Alba, et al.
Publicado: (2022)

Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters
por: Fernández, Laura, et al.
Publicado: (2018)

Virus synthesis and replication: reovirus vs. vaccinia virus.
por: Joklik, W. K.
Publicado: (1980)

Murine alveolar macrophages limit replication of vaccinia virus
por: Rivera, Rachel, et al.
Publicado: (2007)

Vaccinia virus as a subhelper for AAV replication and packaging
por: Moore, Andrea R, et al.
Publicado: (2015)

Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome
por: Delaloye, Julie, et al.
Publicado: (2009)

Antigen Gene Transfer to Human Plasmacytoid Dendritic Cells Using Recombinant Adenovirus and Vaccinia Virus Vectors
por: Bontkes, Hetty J., et al.
Publicado: (2005)

Species-Specific Conservation of Linear Antigenic Sites on Vaccinia Virus A27 Protein Homologs of Orthopoxviruses
por: Ahsendorf, Henrike P., et al.
Publicado: (2019)

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
por: Altenburg, Arwen F., et al.
Publicado: (2017)

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens
por: Nájera, José Luis, et al.
Publicado: (2010)

Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens
por: Perdiguero, Beatriz, et al.
Publicado: (2012)

A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination
por: Huang, Xiaoxing, et al.
Publicado: (2009)

Hepatitis B Virus Induces IL-23 Production in Antigen Presenting Cells and Causes Liver Damage via the IL-23/IL-17 Axis
por: Wang, Qinghong, et al.
Publicado: (2013)

Vaccinia Virus–Encoded Ribonucleotide Reductase Subunits Are Differentially Required for Replication and Pathogenesis
por: Gammon, Don B., et al.
Publicado: (2010)

Vaccinia virus replication is not affected by APOBEC3 family members
por: Kremer, Melanie, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_spvqg3m1lggc4sarpg0ganm4f4